logo
Plus   Neg
Share
Email
Comment

Array BioPharma Enters Into Clinical Trial Collaboration Agreement With Pfizer

Array BioPharma Inc. (ARRY) said it has entered into a clinical trial collaboration agreement with Pfizer Inc. (PFE) to investigate the safety and efficacy of several novel anti-cancer combinations.

This includes Array's MEK inhibitor, binimetinib, with Pfizer's investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.

The two companies entered into this collaboration to explore the potential benefits of combining molecularly targeted therapeutics with the body's innate cancer-fighting abilities using immunotherapy.

Under the terms of the agreement, Array and Pfizer will collaborate on a Phase 1b clinical trial to explore a series of novel combinations, investigating the safety and efficacy of the combination of binimetinib, avelumab and talazoparib across various tumor types.

The companies expect a multi-arm clinical trial to establish recommended doses of different regimens combining the drugs. Initially the focus will be in non-small cell lung cancer or NSCLC and pancreatic cancer, and additional indications will be explored at a later stage.

The study is expected to begin by the third quarter of 2018, and results will be used to determine optimal approaches to further clinical development of these combinations.

Under the collaboration agreement, the trial will be sponsored and funded by Pfizer, with Array providing binimetinib supply.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BlackRock Inc., the world's largest asset manager, said it plans to speak with gun makers and distributors following public outcry after the Florida high school shooting that killed 17 people. BlackRock, which had $6.3 trillion in assets under management as of December 31, 2017, holds shares in gun makers Sturm Ruger & Co. Inc. as well as American Outdoor Brands Corp. An upgraded boarding in Southwest Airline will cost you more. The airline usually not assign seats to passengers, but one can choose from an open seat. The Upgraded Boarding will allow passengers to choose from A1 - A15 boarding positions. The cost for these positions would be $30, $40 and $50, depending on flight and route. This option can be availed from the ticket counter or gate. Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup.
comments powered by Disqus
Follow RTT